Amphastar Pharmaceuticals (NASDAQ:AMPH)‘s stock had its “buy” rating reiterated by equities research analysts at Wells Fargo in a report released on Wednesday.
AMPH has been the topic of several other reports. BidaskClub raised Amphastar Pharmaceuticals from a “strong sell” rating to a “sell” rating in a research report on Friday, January 19th. Zacks Investment Research raised Amphastar Pharmaceuticals from a “sell” rating to a “hold” rating in a research report on Tuesday, January 2nd. Needham & Company LLC raised their price target on Amphastar Pharmaceuticals from $20.00 to $23.00 and gave the company a “buy” rating in a research report on Friday, December 1st. Piper Jaffray Companies reaffirmed a “buy” rating and issued a $26.00 price target on shares of Amphastar Pharmaceuticals in a research report on Tuesday, January 30th. Finally, BMO Capital Markets reaffirmed a “market perform” rating and issued a $19.00 price target (up from $17.00) on shares of Amphastar Pharmaceuticals in a research report on Tuesday, March 13th. One equities research analyst has rated the stock with a sell rating, four have issued a hold rating and four have issued a buy rating to the company’s stock. The company has a consensus rating of “Hold” and an average price target of $21.33.
Shares of AMPH stock opened at $19.51 on Wednesday. The stock has a market capitalization of $901.06, a PE ratio of 216.78, a PEG ratio of 1.38 and a beta of 1.46. Amphastar Pharmaceuticals has a 1 year low of $13.15 and a 1 year high of $20.45. The company has a debt-to-equity ratio of 0.12, a current ratio of 2.79 and a quick ratio of 1.85.
Amphastar Pharmaceuticals (NASDAQ:AMPH) last issued its quarterly earnings results on Monday, March 12th. The company reported $0.10 earnings per share (EPS) for the quarter, beating the Thomson Reuters’ consensus estimate of $0.07 by $0.03. The company had revenue of $60.40 million for the quarter, compared to the consensus estimate of $60.62 million. Amphastar Pharmaceuticals had a return on equity of 4.56% and a net margin of 1.88%. The firm’s revenue was down 4.9% compared to the same quarter last year. During the same period last year, the business posted $0.01 earnings per share. sell-side analysts predict that Amphastar Pharmaceuticals will post 0.63 EPS for the current year.
In related news, Director Richard K. Prins sold 16,598 shares of Amphastar Pharmaceuticals stock in a transaction dated Thursday, March 15th. The stock was sold at an average price of $19.90, for a total transaction of $330,300.20. Following the sale, the director now directly owns 45,442 shares of the company’s stock, valued at $904,295.80. The transaction was disclosed in a document filed with the SEC, which can be accessed through this link. Also, insider Jason B. Shandell sold 20,000 shares of Amphastar Pharmaceuticals stock in a transaction dated Tuesday, March 20th. The stock was sold at an average price of $19.43, for a total value of $388,600.00. Following the sale, the insider now directly owns 251,372 shares in the company, valued at $4,884,157.96. The disclosure for this sale can be found here. Over the last three months, insiders have sold 84,387 shares of company stock worth $1,659,763. 11.10% of the stock is owned by company insiders.
A number of hedge funds have recently added to or reduced their stakes in AMPH. Millennium Management LLC grew its position in Amphastar Pharmaceuticals by 1,746.9% during the fourth quarter. Millennium Management LLC now owns 293,672 shares of the company’s stock worth $5,650,000 after buying an additional 277,771 shares in the last quarter. Dimensional Fund Advisors LP boosted its holdings in Amphastar Pharmaceuticals by 17.0% during the third quarter. Dimensional Fund Advisors LP now owns 1,558,113 shares of the company’s stock valued at $27,844,000 after purchasing an additional 226,271 shares in the last quarter. Wells Fargo & Company MN boosted its holdings in Amphastar Pharmaceuticals by 156.1% during the fourth quarter. Wells Fargo & Company MN now owns 176,323 shares of the company’s stock valued at $3,392,000 after purchasing an additional 107,486 shares in the last quarter. Alliancebernstein L.P. boosted its holdings in Amphastar Pharmaceuticals by 148.9% during the fourth quarter. Alliancebernstein L.P. now owns 113,520 shares of the company’s stock valued at $2,184,000 after purchasing an additional 67,920 shares in the last quarter. Finally, Argent Capital Management LLC boosted its holdings in Amphastar Pharmaceuticals by 102.6% during the third quarter. Argent Capital Management LLC now owns 121,275 shares of the company’s stock valued at $2,167,000 after purchasing an additional 61,425 shares in the last quarter. 44.82% of the stock is currently owned by institutional investors and hedge funds.
COPYRIGHT VIOLATION NOTICE: This piece of content was published by The Ledger Gazette and is the sole property of of The Ledger Gazette. If you are accessing this piece of content on another site, it was illegally copied and republished in violation of U.S. and international trademark & copyright laws. The original version of this piece of content can be accessed at https://ledgergazette.com/2018/03/22/wells-fargo-reiterates-buy-rating-for-amphastar-pharmaceuticals-amph.html.
About Amphastar Pharmaceuticals
Amphastar Pharmaceuticals, Inc is a specialty pharmaceutical company. The Company focuses primarily on developing, manufacturing, marketing and selling generic and injectable, inhalation and intranasal products. The Company has two segments: finished pharmaceutical products and active pharmaceutical ingredients (API) products.
Receive News & Ratings for Amphastar Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Amphastar Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.